M. Haruta

发表

RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.

A. Nakagawara, Y. Kaneko, T. Kamijo, 2014, Cancer letters.

Centrosome amplification is correlated with ploidy divergence, but not with MYCN amplification, in neuroblastoma tumors.

Y. Tsunematsu, Y. Kaneko, A. Kikuta, 2009, Cancer genetics and cytogenetics.

Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma

Y. Arai, M. Ohira, A. Nakagawara, 2008, British Journal of Cancer.

Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities

Y. Arai, M. Fukuzawa, Y. Kaneko, 2008, Genes, chromosomes & cancer.

Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma

Y. Tsunematsu, Y. Kaneko, F. Sasaki, 2007, Pediatric blood & cancer.

Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li‐Fraumeni or Li‐Fraumeni‐like syndrome

Y. Arai, Y. Kaneko, K. Akagi, 2011, Genes, chromosomes & cancer.

Two candidate tumor suppressor genes, MEOX2 and SOSTDC1, identified in a 7p21 homozygous deletion region in a Wilms tumor

Y. Arai, M. Fukuzawa, Y. Kaneko, 2009, Genes, chromosomes & cancer.

Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children

Y. Arai, M. Fukuzawa, Y. Kaneko, 2012, Cancer science.

The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients

M. Ohira, A. Nakagawara, S. Todo, 2008, International journal of cancer.

Experience-Driven Axon Retraction without Binocular Imbalance in Developing Visual Cortex

Y. Hata, M. Haruta, 2007, Current Biology.

Yolk sac tumor but not seminoma or teratoma is associated with abnormal epigenetic reprogramming pathway and shows frequent hypermethylation of various tumor suppressor genes

Y. Arai, Y. Tsunematsu, Y. Kaneko, 2009, Cancer science.

EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications

H. Aburatani, M. Ohira, A. Nakagawara, 2018, Oncogene.

BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA‐like breast cancers treated with neoadjuvant chemotherapy

S. Ogawa, M. Kurosumi, Yusuke Sato, 2017, Genes, chromosomes & cancer.

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

S. Ogawa, M. Kurosumi, A. Sato-Otsubo, 2013, BMC Cancer.

Combined Genetic and Chromosomal Characterization of Wilms Tumors Identifies Chromosome 12 Gain as a Potential New Marker Predicting a Favorable Outcome12

Y. Arai, M. Fukuzawa, Y. Kaneko, 2018, Neoplasia.

Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor

Y. Arai, M. Fukuzawa, Y. Kaneko, 2012, Pediatric blood & cancer.

Genome‐wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma

Y. Arai, A. Nakagawara, Y. Kaneko, 2010, Genes, chromosomes & cancer.

Platelet-to-Lymphocyte Ratio Predicts the Efficacy of Pembrolizumab in Patients With Urothelial Carcinoma

K. Ando, T. Kamijo, M. Inoue, 2022, AntiCancer Research.

Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin‐like growth factor–II in Wilms tumor

Y. Tsunematsu, M. Fukuzawa, Y. Kaneko, 2006, Genes, chromosomes & cancer.

Outcome of renal tumors registered in Japan Wilms Tumor Study‐2 (JWiTS‐2): A report from the Japan Children's Cancer Group (JCCG)

E. Inoue, M. Fukuzawa, Y. Kaneko, 2018, Pediatric blood & cancer.

A high incidence of WT1 abnormality in bilateral Wilms tumours in Japan, and the penetrance rates in children with WT1 germline mutation

Y. Arai, M. Fukuzawa, Y. Kaneko, 2015, British Journal of Cancer.

Anaplastic histology Wilms’ tumors registered to the Japan Wilms’ Tumor Study Group are less aggressive than that in the National Wilms’ Tumor Study 5

M. Fukuzawa, Y. Kaneko, Yukichi Tanaka, 2016, Pediatric Surgery International.

A new imprinted cluster on the human chromosome 7q21-q31, identified by human-mouse monochromosomal hybrids.

Mitsuo Oshimura, M. Meguro, M. Oshimura, 2003, Genomics.

Predominant maternal expression of the mouse Atp10c in hippocampus and olfactory bulb

M. Meguro, A. Kashiwagi, M. Oshimura, 2003, Journal of Human Genetics.

Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma

M. Ohira, K. Ando, T. Kamijo, 2021, Oncogenesis.

Narrowed abrogation of the Angelman syndrome critical interval on human chromosome 15 does not interfere with epigenotype maintenance in somatic cells

M. Meguro, K. Mitsuya, A. Kashiwagi, 2005, Journal of Human Genetics.

Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group

E. Inoue, M. Fukuzawa, Y. Kaneko, 2019, Pediatrics international : official journal of the Japan Pediatric Society.

Meiosis error and subsequent genetic and epigenetic alterations invoke the malignant transformation of germ cell tumor

Y. Arai, Y. Kaneko, T. Ariga, 2013, Genes, chromosomes & cancer.

Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or mixed type

M. Fukuzawa, Y. Kaneko, H. Soejima, 2007, Genes, chromosomes & cancer.

Combined BubR1 protein down‐regulation and RASSF1A hypermethylation in Wilms tumors with diverse cytogenetic changes

M. Fukuzawa, Y. Kaneko, S. Matsuura, 2008, Molecular carcinogenesis.

CFC1 is a cancer stemness-regulating factor in neuroblastoma

M. Kurosumi, M. Ohira, T. Kamijo, 2017, Oncotarget.

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors

M. Ohira, K. Ando, T. Kamijo, 2023, BMC Cancer.

Polycomb EZH1 regulates cell cycle/5‐fluorouracil sensitivity of neuroblastoma cells in concert with MYCN

M. Ohira, K. Ando, T. Kamijo, 2022, Cancer science.

Paternally inherited WT1 mutation plus uniparental disomy of 11p may be an essential mechanism for development of WT1‐mutated familial Wilms tumor

Y. Kaneko, S. Yoshihara, Yuya Sato, 2018, Pediatric blood & cancer.

Frequent breakpoints of focal deletion and uniparental disomy in 22q11.1 or 11.2 segmental duplication region reveal distinct tumorigenesis in rhabdoid tumor of the kidney

Y. Arai, Y. Kaneko, T. Kamijo, 2021, Genes, chromosomes & cancer.

Development of an osteosarcoma model with MYCN amplification and TP53 mutation in hiPS cell‐derived neural crest cells

M. Ohira, T. Kamijo, J. Toguchida, 2023, Cancer science.

Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates

Hiromu Suzuki, Y. Kaneko, T. Kamijo, 2016, Cancer science.

RASSF1A methylation indicates a poor prognosis in hepatoblastoma patients

Hiromu Suzuki, Y. Kaneko, T. Kamijo, 2013, Pediatric Surgery International.

Pretreatment Hemoglobin Levels and Platelet-to-Lymphocyte Ratio Predict Survival Benefit from Pembrolizumab in Advanced Urothelial Carcinoma.

K. Ando, T. Kamijo, Ritsuko Onuki, 2023, Cancer Diagnosis & Prognosis.

Positive regulatory loop of platelet-derived growth factor DD-induced STAT3 activation is associated with poor prognosis in advanced urothelial carcinoma.

K. Ando, T. Kamijo, Ritsuko Onuki, 2023, Biochemical and biophysical research communications.